Add BrightSurf on Google Email

Ludwig Cancer research study finds way to revive potent immune cells for cancer therapy

A Ludwig Cancer Research study has discovered how to revive terminally exhausted T lymphocytes, found within tumors, for cancer therapy by using an immune factor called interleukin-10. This revival restores their potent anti-cancer activity, leading to tumor regression and cures in mouse models of melanoma and colon cancer.

SourceLudwig Institute for Cancer Research·JournalNature Immunology·DateMay 24, 2021

'No level of smoke exposure is safe'

A study by Virginia Commonwealth University researchers found that secondhand smoke exposure during pregnancy is associated with epigenetic changes in babies, which can increase the risk of developmental disorders and cancer. The study analyzed data from over 100 pregnant women and found correlations between low levels of cotinine, a n...

SourceVirginia Commonwealth University·JournalEnvironmental Health Perspectives·DateMay 19, 2021

Cataloging breast cells to find cancer origins

The study created a comprehensive catalog of healthy breast tissue cells, enabling scientists to pinpoint the origin of abnormal changes. By tracking gene activity in over 15,000 cells, the team redefined healthy breast tissue and identified subpopulations with different responses to therapies.

SourceCold Spring Harbor Laboratory·JournalJournal of Mammary Gland Biology and Neoplasia·DateMay 14, 2021

Gene therapy offers potential cure to children born without an immune system

A new form of gene therapy has successfully treated 48 out of 50 children born with a rare and deadly inherited disorder. The treatment, developed by an international team, involves delivering a corrected copy of the ADA gene into stem cells, which are then returned to the child's body to produce healthy immune cells.

SourceUniversity of California - Los Angeles Health Sciences·JournalNew England Journal of Medicine·DateMay 11, 2021

Antiviral T cells safe and effective for treating debilitating complication common after stem cell transplants

A Phase II trial found that BKV-specific T cells from healthy donors are safe and effective in treating debilitating complications after stem cell transplants. Patients experienced rapid responses, with 81.6% showing improvement after 28 days, and no cases of severe GVHD or toxicities.

SourceUniversity of Texas M. D. Anderson Cancer Center·JournalJournal of Clinical Oncology·DateApr 30, 2021

Designing healthy diets - with computer analysis

A new mathematical model developed by Chalmers University of Technology can predict how different bacteria interact and affect the intestinal microbiome. The model was tested on two clinical studies, one involving Swedish infants and another adults in Finland, showing high accuracy in predicting multiple variables.

SourceChalmers University of Technology·JournalProceedings of the National Academy of Sciences·DateApr 20, 2021

Acta Pharmaceutica Sinica B Volume 11, Issue 3 publishes

This issue of APSB features studies on protecting against doxorubicin-induced cardiotoxicity via increasing YAP1 expression, as well as investigating alternative strategies to downregulate PD-L1 in gastric cancer cells. The journal also publishes research on a novel injectable micelle-hydrogel hybrid for localized drug delivery and tar...

SourceCompuscript Ltd·JournalActa Pharmaceutica Sinica B·DateApr 15, 2021

Text me about cervical cancer

Research from Michigan State University highlights the racial disparity gap in cervical cancer information and follow-up, citing poor provider-patient communication as a key factor. The study suggests that improving education and using digital channels like text messages can help bridge this gap.

SourceMichigan State University·JournalGynecologic Oncology·DateMar 17, 2021

A new co-driver in breast cancer

UC researchers found that cooperation between HER2 and MED1 genes promotes breast tumor growth, spread, and treatment resistance. Targeting MED1 alone or in combination with current therapies may be an effective treatment strategy for nearly 90% of breast cancer patients.

SourceUniversity of Cincinnati·JournalCell Reports·DateMar 9, 2021

More collaboration between primary care and oncology may improve fragmented cancer care

Researchers conducted a randomized intervention that improved continuity of care and interprofessional collaboration between lung cancer patients and their family physicians. The bidirectional exchange of patient information and care summaries led to enhanced patient and family physician perceptions of care, resulting in better outcomes.

SourceAmerican Academy of Family Physicians·JournalThe Annals of Family Medicine·DateMar 9, 2021

Oncotarget: Identification intermediate-risk subgroups in metastatic clear-cell renal cell carcinoma

A recent study published in Oncotarget identified elevated platelet counts as a prognostic factor for poor outcomes in patients with metastatic clear-cell renal cell carcinoma, particularly those classified as intermediate-risk. These findings highlight the importance of stratification models in guiding treatment decisions and design c...

SourceImpact Journals LLC·JournalOncotarget·DateMar 1, 2021